The global neurovascular devices market was valued at USD 3.19 billion in 2024 and is projected to expand at a compound annual growth rate (CAGR) of 6.01% from 2025 to 2030. This growth is primarily fueled by the increasing prevalence of neurovascular disorders, ongoing advancements in medical technologies, and a growing emphasis on minimally invasive procedures. As conditions like strokes, cerebral aneurysms, and Arteriovenous Malformations (AVM) become more widespread, the demand for effective treatment options continues to rise.

Interventional neurology devices play a crucial role in diagnosing and treating disorders affecting the central nervous system and brain vasculature. These procedures include endovascular techniques, catheter-based interventions, angiography, and fluoroscopy. Catheter angiography is one of the oldest in vivo imaging techniques for the brain's vascular system, enabling the diagnosis of various neurological conditions such as cerebral aneurysms, arteriovenous malformations, intracranial stenosis, arteriovenous fistulas, and vasculitis.

Gather more insights about the market drivers, restrains and growth of the Neurovascular Devices Market

The growing incidence of neurovascular diseases, particularly strokes and aneurysms, significantly drives the neurovascular devices market. A range of neurovascular devices, including clot retrieval devices, microcatheters, and flow diversion coils, is employed to address these health issues. According to the Global Stroke Fact Sheet 2022 released by the World Stroke Organization (WSO), over 12.2 million new strokes occur each year, with around 25% of individuals over the age of 25 expected to experience a stroke at some point in their lives.

Device Segmentation Insights

Cerebral embolization and aneurysm coiling devices accounted for the largest market share, approximately 36.02%, in 2024. Coil embolization is a minimally invasive technique used for treating aneurysms, where a coil-like material is introduced to close off the aneurysm sac, thereby significantly reducing the risk of bleeding. This procedure involves the insertion of a steerable catheter through the groin, which is then carefully navigated to the brain. The increasing prevalence of aneurysms is anticipated to further boost the growth of this segment throughout the forecast period. These devices are categorized into several types, including embolic coils, flow diversion devices, and liquid embolic agents. A notable example of innovation in this area occurred in January 2023 when Luidx Medical Technologies, Inc. announced the successful application of the Embolic IMPASS Device in in-vivo research related to meningeal middle artery (MMA) embolization. This technique offers a treatment option for chronic subdural hematomas located on the brain's surface, presenting a minimally invasive alternative to traditional surgical interventions.

On the other hand, the neurothrombectomy devices segment is expected to experience the highest compound annual growth rate (CAGR) of 7.13% during the forecast period. This anticipated growth is driven by an increasing number of strategic initiatives among key market players, which include product launches, mergers and acquisitions, and other growth strategies, as well as the rising incidence of acute ischemic strokes. For example, in January 2023, Therma Bright Inc. made an investment in Inretio Inc., an Israeli startup specializing in ischemic stroke blood clot retrieval technologies. The PREVA basket is designed to "ensnare" clots, effectively enclosing them and protecting the brain from potential sub-clots that may dislodge during the thrombectomy process.

Moreover, in February 2024, Perfuze, a company focused on developing next-generation catheter-based aspiration technologies for treating acute ischemic strokes caused by major artery obstructions, successfully completed a USD 23.94 million Series A financing round. Additionally, Rapid Medical, a developer of innovative neurovascular devices, announced that its TIGERTRIEVER 13 device received FDA 510(k) clearance during the 19th Annual Conference of the Society of NeuroInterventional Surgery (SNIS) held in Toronto in 2024. The TIGERTRIEVER 13 is recognized as the world's smallest revascularization device, specifically engineered to remove thrombus from delicate brain blood vessels following an ischemic stroke, underscoring its importance in enhancing patient outcomes.

Order a free sample PDF of the Market Intelligence Study, published by Grand View Research.